Sofia Hassiotis Selected Research

N-sulfoglucosamine sulfohydrolase (sulfamidase)

1/2017	Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA.
1/2017	A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.
5/2016	Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.
5/2016	A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.
4/2016	Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder.
1/2016	Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain.
5/2015	Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.
3/2015	Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.
1/2015	Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods.
1/2013	Neonatal Bone Marrow Transplantation in MPS IIIA Mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sofia Hassiotis Research Topics

Disease

17	Mucopolysaccharidosis III (Sanfilippo Syndrome) 01/2017 - 03/2009
4	Gliosis 01/2017 - 03/2009
3	Mucopolysaccharidoses 01/2017 - 01/2013
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 04/2016
2	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 01/2018
2	Neuroinflammatory Diseases 01/2016 - 05/2015
1	Sandhoff Disease (Sandhoff's Disease) 06/2022
1	Tay-Sachs Disease 06/2022
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 06/2022
1	Chronic Disease (Chronic Diseases) 10/2021
1	Amyloid Plaque 01/2018
1	Nervous System Diseases (Neurological Disorders) 05/2016
1	Brain Diseases (Brain Disorder) 04/2016
1	Infections 01/2016

Drug/Important Bio-Agent (IBA)

15	N-sulfoglucosamine sulfohydrolase (sulfamidase)IBA 01/2017 - 03/2009
11	EnzymesIBA 01/2017 - 07/2011
7	Heparitin Sulfate (Heparan Sulfate)IBA 01/2017 - 10/2010
3	Amyloid (Amyloid Fibrils)IBA 06/2022 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 10/2021 - 03/2015
3	OligosaccharidesIBA 05/2016 - 03/2009
3	GlycolipidsIBA 05/2015 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 03/2009
2	UbiquitinIBA 01/2017 - 03/2009
2	Lysosomal Membrane ProteinsIBA 01/2017 - 01/2016
2	GangliosidesIBA 04/2016 - 08/2011
1	Hexosaminidases (Hexosaminidase)IBA 06/2022
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2017
1	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2017
1	Glutamic Acid (Glutamate)FDA Link 01/2017
1	Cholinergic Agents (Cholinergics)IBA 01/2017
1	Filipin (Filipin III)IBA 01/2016
1	Glial Fibrillary Acidic ProteinIBA 01/2016
1	LectinsIBA 01/2016
1	G(M3) GangliosideIBA 01/2016
1	LipidsIBA 01/2016
1	Protein AggregatesIBA 06/2014
1	Green Fluorescent ProteinsIBA 01/2013
1	CholesterolIBA 08/2011
1	Polysaccharides (Glycans)IBA 07/2011
1	mannose-6-phosphateIBA 07/2011

Therapy/Procedure

4	Cannula 01/2017 - 01/2016
2	Enzyme Replacement Therapy 05/2016 - 05/2015
1	Spinal Infusions 01/2017
1	Infusion Pumps (Infusion Pump) 05/2016
1	Therapeutics 05/2016
1	Injections 01/2016
1	Spinal Injections 01/2015
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2013
1	Stem Cell Transplantation 10/2010